May 6, 2021 -- Dyno Therapeutics has closed $100 million in financing to expand its CapsidMap platform, which uses artificial intelligence (AI) technology to design novel adeno-associated virus (AAV) gene therapy vectors, thereby enhancing the therapeutic effect of gene therapies.
CapsidMap optimizes capsids, the cell-targeting protein shells of AAV vectors. Specifically, Dyno will use the funds to design improved vectors targeting liver, muscle, eye, and central nervous system diseases, as well as new areas such as lung, heart, and kidney disease.
Dyno will also support multiple partnership efforts with gene therapy biopharmaceutical companies by increasing its operations, intellectual property portfolio, and business development teams. The company has existing partnerships for AAV vectors with Novartis, Sarepta, and Roche. Dyno plans to increase its employee base across science, machine learning, and business functions to support existing and potential partners.
The series A financing was led by Andreessen Horowitz.
Copyright © 2021 scienceboard.net